Providence Health & Services

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1859-01-01

Employees: 10K

Market Cap: -

Website: http://www.providence.org

Clinical Trials

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: M3T01
Drug: Pembrolizumab
Radiation: Chemoradiation
Drug: FOLFOX regimen

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: Providence Health & Services

Target Recruit Count: 110

Registration Number: NCT06719362

Locations: 🇺🇸
Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States

Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients

Phase 2

Not yet recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Pembrolizumab
Drug: INBRX-106

First Posted Date: 2024-04-09

Last Posted Date: 2024-07-26

Lead Sponsor: Providence Health & Services

Target Recruit Count: 12

Registration Number: NCT06353997

Locations: 🇺🇸
Ellison Institute of Technology (EITM), Los Angeles, California, United States
🇺🇸
Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States
🇺🇸
Providence St. Vincent Medical Center, Portland, Oregon, United States

and more 1 locations

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Phase 2

Recruiting

Conditions: Primary Central Nervous System Lymphoma

Interventions: Procedure: Cognitive Assessment
Biological: Obinutuzumab
Other: Quality of Life Assessment

First Posted Date: 2023-12-18

Last Posted Date: 2024-03-20

Lead Sponsor: Providence Health & Services

Target Recruit Count: 30

Registration Number: NCT06175000

Locations: 🇺🇸
Providence St. Vincent Medical Center, Portland, Oregon, United States

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Metastatic Melanoma
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: GB1211
Drug: Pembrolizumab
Drug: Placebo

First Posted Date: 2023-06-22

Last Posted Date: 2024-04-09

Lead Sponsor: Providence Health & Services

Target Recruit Count: 92

Registration Number: NCT05913388

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

Clinical Outcomes and Patient Satisfaction With Use of the Amma System

Active, not recruiting

Conditions: Breast Cancer

Interventions: Device: Amma Cooling Caps

First Posted Date: 2022-08-19

Last Posted Date: 2024-10-26

Lead Sponsor: Providence Health & Services

Target Recruit Count: 15

Registration Number: NCT05508984

Locations: 🇺🇸
Providence Cancer Institute - Newberg Clinic, Newberg, Oregon, United States
🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸
Providence Oncology and Hematology Care - Westside, Portland, Oregon, United States

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Conditions: KRAS G12V Mutant Advanced Epithelial Cancers

First Posted Date: 2022-05-25

Last Posted Date: 2024-10-26

Lead Sponsor: Providence Health & Services

Registration Number: NCT05389514

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Phase 1

Active, not recruiting

Conditions: Malignant Epithelial Neoplasms

Interventions: Biological: TCR-transduced T cells
Drug: CDX-1140
Drug: Pembrolizumab

First Posted Date: 2022-04-27

Last Posted Date: 2024-11-25

Lead Sponsor: Providence Health & Services

Target Recruit Count: 1

Registration Number: NCT05349890

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma, Uveal

Interventions: Drug: Pembrolizumab
Drug: Lenvatinib

First Posted Date: 2022-04-04

Last Posted Date: 2024-12-05

Lead Sponsor: Providence Health & Services

Target Recruit Count: 6

Registration Number: NCT05308901

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Phase 1

Active, not recruiting

Conditions: Neuroendocrine Tumors

Interventions: Drug: Cabozantinib
Drug: Lu-177

First Posted Date: 2022-02-21

Last Posted Date: 2024-01-25

Lead Sponsor: Providence Health & Services

Target Recruit Count: 6

Registration Number: NCT05249114

Locations: 🇺🇸
Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Phase 2

Completed

Conditions: Refractory Cutaneous Melanoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab
Drug: Cabozantinib

First Posted Date: 2022-01-20

Last Posted Date: 2024-07-25

Lead Sponsor: Providence Health & Services

Target Recruit Count: 4

Registration Number: NCT05200143

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy